Paper Details

  1. Home
  2. Paper Details

A randomized pilot trial of low-dose combination lipid-lowering therapy following coronary artery bypass grafting.

Author: BarbirM, GallowayD, HuntB J, IlsleyC, MitchellA, TaylorA, YacoubM

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study found that low-dose combinations of colestipol and simvastatin or colestipol and bezafibrate were effective and well tolerated in the management of moderate hyperlipidemia in patients who had undergone coronary artery bypass grafting.
Paper Details　
Original Abstract of the Article :
Vein graft atherosclerosis is a common and serious complication of coronary artery bypass grafting (CABG). There is mounting evidence that lipoprotein abnormalities play an equally important role in the development of lesions in saphenous vein grafts after CABG as in native coronary vessel disease. ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/clc.4960170204

データ提供：米国国立医学図書館（NLM）

A New Approach to Vein Graft Atherosclerosis: Low-Dose Lipid-Lowering Therapy

The world of [coronary artery bypass grafting (CABG)] is intricate and complex, much like the shifting sands of a desert. Understanding the potential complications and developing effective strategies for managing them is crucial for optimizing patient outcomes. This study, like a seasoned explorer, investigates the efficacy and safety of [low-dose combination lipid-lowering therapy] in patients following CABG, seeking to address the challenge of [vein graft atherosclerosis].

Low-Dose Lipid-Lowering Therapy: A New Oasis in the CABG Desert

The study found that both [colestipol and simvastatin] and [colestipol and bezafibrate] combinations effectively reduced lipid levels in patients following CABG, with no significant side effects. This discovery is like finding a hidden spring in the desert, offering a promising approach to managing vein graft atherosclerosis. The researchers highlight the potential of these low-dose combinations to improve lipid profiles and potentially reduce the risk of graft atherosclerosis.

Navigating the Post-CABG Landscape

This study underscores the importance of addressing lipid abnormalities following CABG. It's like navigating a desert with a compass, guiding clinicians towards a more effective and personalized approach to managing post-CABG care. The study's findings suggest that low-dose lipid-lowering therapy may offer a valuable tool for reducing the risk of vein graft atherosclerosis and improving long-term outcomes for patients. This research provides valuable insights into the complex world of post-CABG management, guiding us towards more effective and patient-centered care.

Dr.Camel's Conclusion

This research, like a caravan traversing a desert, reveals the potential of low-dose combination lipid-lowering therapy to improve lipid profiles and potentially reduce the risk of vein graft atherosclerosis in patients following CABG. It underscores the importance of addressing lipid abnormalities to optimize long-term outcomes for these individuals.

Date :
  1. Date Completed 1994-05-23
  2. Date Revised 2019-05-12
Further Info :

Pubmed ID

8162627

DOI: Digital Object Identifier

10.1002/clc.4960170204

Related Literature

Article Analysis
・Side Effects of colestipol
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.